| Title |
Tocopherol (Vitamin E) in Alzheimer’s Disease and Other Neurodegenerative Disorders
|
|---|---|
| Published in |
CNS Drugs, August 2012
|
| DOI | 10.2165/00023210-200418120-00005 |
| Pubmed ID | |
| Authors |
Karen Berman, Henry Brodaty |
| Abstract |
In this article, we review the evidence that tocopherol (vitamin E) may have a role to play in the prevention and treatment of Alzheimer's disease and other neurological diseases. The theoretical rationale for the effectiveness of tocopherol as treatment and/or prevention of Alzheimer's disease is based on its antioxidant properties. Results from animal and in vitro studies provide evidence to support use of tocopherol for prevention and treatment of degenerative neurological diseases. Furthermore, several, but not all, epidemiological, cross-sectional, prospective studies indicate that tocopherol may have protective effects in Alzheimer's disease, although dietary and supplemental forms of the vitamin may differ in their efficacy. Mixed results have been obtained from clinical trials. Evidence of the use of tocopherol as a protective measure or as therapy in neurological diseases other than Alzheimer's disease is less compelling. To date, there are no clear-cut answers as to whether tocopherol is worth prescribing, but current clinical practice favours its use in the treatment of Alzheimer's disease. |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 62 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 22% |
| Student > Bachelor | 7 | 11% |
| Student > Ph. D. Student | 6 | 10% |
| Student > Doctoral Student | 6 | 10% |
| Professor | 4 | 6% |
| Other | 15 | 24% |
| Unknown | 11 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 21% |
| Biochemistry, Genetics and Molecular Biology | 5 | 8% |
| Agricultural and Biological Sciences | 5 | 8% |
| Psychology | 4 | 6% |
| Nursing and Health Professions | 4 | 6% |
| Other | 13 | 21% |
| Unknown | 19 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2014.
All research outputs
#4,835,465
of 25,373,627 outputs
Outputs from CNS Drugs
#440
of 1,387 outputs
Outputs of similar age
#34,106
of 187,944 outputs
Outputs of similar age from CNS Drugs
#143
of 541 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,387 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,944 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.